Trial Profile
A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety , Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Taspoglutide (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms EMERGE-6; T-EMERGE-6
- Sponsors Roche
- 14 Apr 2016 This trial is prematurely ended in Spain (end date: 11 Jan 2011), UK (end date: 23 Nov 2010), Germany (end date: 31 Jan 2011), Poland (end date: 31 Jan 2011), Slovakia and Italy.
- 18 Apr 2011 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 15 Oct 2010 Planned end date changed from 1 Jul 2012 to 1 Dec 2011 as reported by ClinicalTrials.gov.